Search

Your search keyword '"O’Kelly, James"' showing total 226 results
Start Over Author "O’Kelly, James"
226 results on '"O’Kelly, James"'

2. Kynurenine monooxygenase regulates inflammation during critical illness and recovery in experimental acute pancreatitis

Author

Hayes, Alastair J., Zheng, Xiaozhong, O’Kelly, James, Neyton, Lucile P.A., Bochkina, Natalia A., Uings, Iain, Liddle, John, Baillie, J. Kenneth, Just, George, Binnie, Margaret, Homer, Natalie Z.M., Murray, Toby B.J., Baily, James, McGuire, Kris, Skouras, Christos, Garden, O. James, Webster, Scott P., Iredale, John P., Howie, Sarah E.M., and Mole, Damian J.

Published
2023
Full Text
View/download PDF

9. Evaluating the comparability of osteoporosis treatments using propensity score and negative control outcome methods in UK and Denmark electronic health record databases

Author

Tan, Eng Hooi, primary, Rathod-Mistry, Trishna, additional, Strauss, Victoria Y, additional, O’Kelly, James, additional, Giorgianni, Francesco, additional, Baxter, Richard, additional, Brunetti, Vanessa C, additional, Pedersen, Alma Becic, additional, Ehrenstein, Vera, additional, and Prieto-Alhambra, Daniel, additional

Published
2024
Full Text
View/download PDF

10. Evaluating the comparability of osteoporosis treatments using propensity score and negative control outcome methods in UK and Denmark electronic health record databases

Author

Tan, Eng Hooi, Rathod-Mistry, Trishna, Strauss, Victoria Y., O’Kelly, James, Giorgianni, Francesco, Baxter, Richard, Brunetti, Vanessa C., Pedersen, Alma Becic, Ehrenstein, Vera, Prieto-Alhambra, Daniel, Tan, Eng Hooi, Rathod-Mistry, Trishna, Strauss, Victoria Y., O’Kelly, James, Giorgianni, Francesco, Baxter, Richard, Brunetti, Vanessa C., Pedersen, Alma Becic, Ehrenstein, Vera, and Prieto-Alhambra, Daniel

Abstract

Evidence on the comparative effectiveness of osteoporosis treatments is heterogeneous. This may be attributed to different populations and clinical practice, but also to differing methodologies ensuring comparability of treatment groups before treatment effect estimation and the amount of residual confounding by indication. This study assessed the comparability of denosumab vs oral bisphosphonate (OBP) groups using propensity score (PS) methods and negative control outcome (NCO) analysis. A total of 280 288 women aged ≥50 yr initiating denosumab or OBP in 2011-2018 were included from the UK Clinical Practice Research Datalink (CPRD) and the Danish National Registries (DNR). Balance of observed covariates was assessed using absolute standardized mean difference (ASMD) before and after PS weighting, matching, and stratification, with ASMD >0.1 indicating imbalance. Residual confounding was assessed using NCOs with ≥100 events. Hazard ratio (HR) and 95%CI between treatment and NCO were estimated using Cox models. Presence of residual confounding was evaluated with 2 approaches (1) >5% of NCOs with 95% CI excluding 1, (2) >5% of NCOs with an upper CI <0.75 or lower CI >1.3. The number of imbalanced covariates before adjustment (CPRD 22/87; DNR 18/83) decreased, with 2%–11% imbalance remaining after weighting, matching, or stratification. Using approach 1, residual confounding was present for all PS methods in both databases (≥8% of NCOs), except for stratification in DNR (3.8%). Using approach 2, residual confounding was present in CPRD with PS matching (5.3%) and stratification (6.4%), but not with weighting (4.3%). Within DNR, no NCOs had HR estimates with upper or lower CI limits beyond the specified bounds indicating residual confounding for any PS method. Achievement of covariate balance and determination of residual bias were dependent upon several factors including the population under study, PS method, prevalence of NCO, and the threshold indic

Published
2024

12. Evaluating the comparability of osteoporosis treatments using propensity score and negative control outcome methods in UK and Denmark electronic health record databases

Author

Rathod-Mistry, Trishna, primary, Tan, Eng Hooi, additional, Strauss, Victoria Y, additional, O’Kelly, James, additional, Giorgianni, Francesco, additional, Baxter, Richard, additional, Brunetti, Vanessa C, additional, Pedersen, Alma Becic, additional, Ehrenstein, Vera, additional, and Prieto-Alhambra, Daniel, additional

Published
2023
Full Text
View/download PDF

15. Real world evidence : Perspectives from a European Society of Cardiology Cardiovascular Round Table with contribution from the European Medicines Agency

Author

Szymanski, Piotr, Weidinger, Franz, Lordereau-Richard, Isabelle, Himmelmann, Anders, Arca, Marcello, Chaves, Jose, Lee, Charles, Jonker, Carla, Kotecha, Dipak, O'Kelly, James, Plueschke, Kelly, Rys, Andrzej, Segec, Andrej, Wallentin, Lars, Veltrop, Rogier, James, Stefan, Szymanski, Piotr, Weidinger, Franz, Lordereau-Richard, Isabelle, Himmelmann, Anders, Arca, Marcello, Chaves, Jose, Lee, Charles, Jonker, Carla, Kotecha, Dipak, O'Kelly, James, Plueschke, Kelly, Rys, Andrzej, Segec, Andrej, Wallentin, Lars, Veltrop, Rogier, and James, Stefan

Abstract

Real world data (RWD) refers to healthcare information that is routinely collected in electronic healthcare records (EHR), hospital and pharmacy records, patient and disease registries, and health insurance databases. The collection and analysis of this vast amount of data is an important complement to that obtained from conventional randomised controlled trials (RCT). Real world data has been used for healthcare quality improvements, to conduct clinical trials, to support drug and device development, and to inform medical guidelines. The utility of RWD may be facilitated by common data models, which standardise format and content, and allow data from different health systems to be analysed together. The European Society of Cardiology (ESC) supports the use of RWD in collaboration with national cardiac societies, regulatory authorities, and industry to encourage continuous quality of care improvements at the hospital and country level, to conduct registry-based randomised clinical trials (R-RCT) and to facilitate safety surveillance of novel drugs and devices. The European Medicines Agency (EMA) is developing systems and processes to enable the use of RWD that can help in trial planning, defining clinical contexts, and enhancing outcome assessments. RWD can also contribute to the measurement of the impact of regulatory actions, such as contraindications or restriction of indications by looking at medicines use patterns over time across European Member States. A number of other initiatives from the European Commission and the EMA are underway to strengthen the EU's health security framework, and foster the collection and utilisation of RWD.

Published
2023
Full Text
View/download PDF

16. Global Epidemiology of Hip Fractures:Secular Trends in Incidence Rate, Post-Fracture Treatment, and All-Cause Mortality

Author

Sing, Chor Wing, Lin, Tzu Chieh, Bartholomew, Sharon, Bell, J. Simon, Bennett, Corina, Beyene, Kebede, Bosco-Levy, Pauline, Bradbury, Brian D., Chan, Amy Hai Yan, Chandran, Manju, Cooper, Cyrus, de Ridder, Maria, Doyon, Caroline Y., Droz-Perroteau, Cécile, Ganesan, Ganga, Hartikainen, Sirpa, Ilomaki, Jenni, Jeong, Han Eol, Kiel, Douglas P., Kubota, Kiyoshi, Lai, Edward Chia Cheng, Lange, Jeff L., Lewiecki, E. Michael, Lin, Julian, Liu, Jiannong, Maskell, Joe, de Abreu, Mirhelen Mendes, O'Kelly, James, Ooba, Nobuhiro, Pedersen, Alma B., Prats-Uribe, Albert, Prieto-Alhambra, Daniel, Qin, Simon Xiwen, Shin, Ju Young, Sørensen, Henrik T., Tan, Kelvin Bryan, Thomas, Tracy, Tolppanen, Anna Maija, Verhamme, Katia M.C., Wang, Grace Hsin Min, Watcharathanakij, Sawaeng, Wood, Stephen J., Cheung, Ching Lung, Wong, Ian C.K., Sing, Chor Wing, Lin, Tzu Chieh, Bartholomew, Sharon, Bell, J. Simon, Bennett, Corina, Beyene, Kebede, Bosco-Levy, Pauline, Bradbury, Brian D., Chan, Amy Hai Yan, Chandran, Manju, Cooper, Cyrus, de Ridder, Maria, Doyon, Caroline Y., Droz-Perroteau, Cécile, Ganesan, Ganga, Hartikainen, Sirpa, Ilomaki, Jenni, Jeong, Han Eol, Kiel, Douglas P., Kubota, Kiyoshi, Lai, Edward Chia Cheng, Lange, Jeff L., Lewiecki, E. Michael, Lin, Julian, Liu, Jiannong, Maskell, Joe, de Abreu, Mirhelen Mendes, O'Kelly, James, Ooba, Nobuhiro, Pedersen, Alma B., Prats-Uribe, Albert, Prieto-Alhambra, Daniel, Qin, Simon Xiwen, Shin, Ju Young, Sørensen, Henrik T., Tan, Kelvin Bryan, Thomas, Tracy, Tolppanen, Anna Maija, Verhamme, Katia M.C., Wang, Grace Hsin Min, Watcharathanakij, Sawaeng, Wood, Stephen J., Cheung, Ching Lung, and Wong, Ian C.K.

Abstract

In this international study, we examined the incidence of hip fractures, postfracture treatment, and all-cause mortality following hip fractures, based on demographics, geography, and calendar year. We used patient-level healthcare data from 19 countries and regions to identify patients aged 50 years and older hospitalized with a hip fracture from 2005 to 2018. The age- and sex-standardized incidence rates of hip fractures, post-hip fracture treatment (defined as the proportion of patients receiving anti-osteoporosis medication with various mechanisms of action [bisphosphonates, denosumab, raloxifene, strontium ranelate, or teriparatide] following a hip fracture), and the all-cause mortality rates after hip fractures were estimated using a standardized protocol and common data model. The number of hip fractures in 2050 was projected based on trends in the incidence and estimated future population demographics. In total, 4,115,046 hip fractures were identified from 20 databases. The reported age- and sex-standardized incidence rates of hip fractures ranged from 95.1 (95% confidence interval [CI] 94.8–95.4) in Brazil to 315.9 (95% CI 314.0–317.7) in Denmark per 100,000 population. Incidence rates decreased over the study period in most countries; however, the estimated total annual number of hip fractures nearly doubled from 2018 to 2050. Within 1 year following a hip fracture, post-hip fracture treatment ranged from 11.5% (95% CI 11.1% to 11.9%) in Germany to 50.3% (95% CI 50.0% to 50.7%) in the United Kingdom, and all-cause mortality rates ranged from 14.4% (95% CI 14.0% to 14.8%) in Singapore to 28.3% (95% CI 28.0% to 28.6%) in the United Kingdom. Males had lower use of anti-osteoporosis medication than females, higher rates of all-cause mortality, and a larger increase in the projected number of hip fractures by 2050. Substantial variations exist in the global epidemiology of hip fractures and postfracture outcomes. Our findings inform possible actions to reduc

Published
2023

17. Treatment persistence and switching patterns of ABP 501 in European patients with inflammatory bowel disease.

Author

Jin, Ran, Kruppert, Silvia, Scholz, Florian, Bardoulat, Isabelle, Karzazi, Khalil, Kricorian, Greg, O'Kelly, James L., and Reinisch, Walter

Subjects
INFLAMMATORY bowel diseases, GERMANS
Abstract

Background: Approval of the adalimumab (ADA) biosimilar ABP 501 for inflammatory bowel disease (IBD) indications was based on the principle of extrapolation, without indication-specific clinical trial data. Objectives: To evaluate the real-world treatment patterns of ABP 501 in patients with IBD. Design: Retrospective analysis of pharmacy claims data from Germany and France. Methods: Continuously insured adult IBD patients who initiated ABP 501 between October 2018 and March 2020 were included. Treatment persistence, adherence, and post-ABP 501 switching patterns were evaluated for two mutually exclusive groups: ADA-naïve patients (i.e. no baseline use of ADA products) and ADA-experienced patients (i.e. previously treated with ADA products). Results: A total of 3362 German patients and 733 French patients were included, with 54.4% and 65.3% being ADA-naïve patients, respectively. Median persistence (95% CI) on ABP 501 was 10.9 months (9.8–11.6) in ADA-naïve patients and 14.2 months (12.7–15.2) in ADA-experienced patients in Germany; for the French cohort, ADA-naïve and -experienced patients had median persistence of 12.8 months (10.2–14.7) and 11.5 months (8.8–14.4), respectively. During the first 12 months of ABP 501 initiation, 53.7% of German patients and 51.0% of French patients were adherent to the therapy. About 20% of patients in both countries switched from ABP 501 to another targeted therapy. In the German cohort, ADA-naïve patients most frequently switched to non-tumor necrosis factor inhibitor biologics, but ADA-experienced patients most commonly switched to reference product (RP); in the French cohort, patients most often switched to RP regardless of prior exposure to ADA products. Conclusion: About 50% of patients persisted on and were adherent to ABP 501 therapy during the first 12 months after treatment initiation in two large European countries. Post-ABP 501, switching patterns varied between countries, indicating diversified treatment practices warranting further research on reason(s) for switching and potential overall treatment outcomes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Global epidemiology of hip fractures: secular trends in incidence rate, post‐fracture treatment, and all‐cause mortality

Author

Sing, Chor‐Wing, primary, Lin, Tzu‐Chieh, additional, Bartholomew, Sharon, additional, J, Simon Bell, additional, Bennett, Corina, additional, Beyene, Kebede, additional, Bosco‐Levy, Pauline, additional, Bradbury, Brian D, additional, Chan, Amy Hai Yan, additional, Chandran, Manju, additional, Cooper, Cyrus, additional, de Ridder, Maria, additional, Y, Caroline Doyon, additional, Droz‐Perroteau, Cécile, additional, Ganesan, Ganga, additional, Hartikainen, Sirpa, additional, Ilomaki, Jenni, additional, Jeong, Han Eol, additional, Kiel, Douglas P, additional, Kubota, Kiyoshi, additional, Chia‐Cheng Lai, Edward, additional, Lange, Jeff L, additional, Lewiecki, E Michael, additional, Lin, Julian, additional, Liu, Jiannong, additional, Maskell, Joe, additional, de Abreu, Mirhelen Mendes, additional, O'Kelly, James, additional, Ooba, Nobuhiro, additional, Pedersen, Alma B, additional, Prats‐Uribe, Albert, additional, Prieto‐Alhambra, Daniel, additional, Qin, Simon Xiwen, additional, Shin, Ju‐Young, additional, Sørensen, Henrik T, additional, Tan, Kelvin Bryan, additional, Thomas, Tracy, additional, Tolppanen, Anna‐Maija, additional, MC, Katia Verhamme, additional, Wang, Grace Hsin‐Min, additional, Watcharathanakij, Sawaeng, additional, J, Stephen Wood, additional, Cheung, Ching‐Lung, additional, and Wong, Ian CK, additional

Published
2023
Full Text
View/download PDF

21. Real world evidence: Perspectives from a European Society of Cardiology Cardiovascular Round Table with contribution from the European Medicines Agency

Author

Szymański, Piotr, primary, Weidinger, Franz, additional, Lordereau-Richard, Isabelle, additional, Himmelmann, Anders, additional, Arca, Marcello, additional, Chaves, Jose, additional, Lee, Charles, additional, Jonker, Carla, additional, Kotecha, Dipak, additional, O'Kelly, James, additional, Plueschke, Kelly, additional, Ryś, Andrzej, additional, Segec, Andrej, additional, Wallentin, Lars, additional, Veltrop, Rogier, additional, and James, Stefan, additional

Published
2023
Full Text
View/download PDF

24. Vitamin D Analogs and Breast Cancer

Author

O’Kelly, James, Koeffler, H. Phillip, Schlag, P. M., editor, Senn, H.-J, editor, Kleihues, P., editor, Stiefel, F., editor, Groner, B., editor, Wallgren, A., editor, Reichrath, Jörg, editor, Tilgen, Wolfgang, editor, and Friedrich, Michael, editor

Published
2003
Full Text
View/download PDF

25. Comparability of Osteoporosis Treatment Groups Among Female Medicare Beneficiaries in the United States.

Author

Min Kim, Tzu-Chieh Lin, Arora, Tarun, Hong Zhao, Balasubramanian, Akhila, Stad, Robert Kees, O'Kelly, James, Spangler, Leslie, Bradbury, Brian D., and Curtis, Jeffrey R.

Abstract

It is often difficult to obtain valid estimates of comparative treatment effectiveness and safety owing to differences across patient populations taking different medications in the real world. One approach for assessing comparability between treatment groups in effectiveness studies is to use negative control outcomes (NCOs). NCOs share similar sources of bias with the primary outcomes but have no plausible causal relationship to the treatment of interest. Observing differences in the risk of NCOs thus provides evidence for residual confounding between groups. This retrospective study assessed the comparability of postmenopausal women, treated with osteoporosis medications with various mechanisms of action such as denosumab (receptor activator of nuclear factor κB ligand [RANKL] inhibitor), zoledronic acid (bisphosphonate derivative), or oral bisphosphonates including alendronate. Administrative claims data were extracted from the US Centers for Medicare and Medicaid Services' Chronic Condition Warehouse database (May 2010-December 2016). Propensity scores were used to match denosumab patients 1:1 to comparators. Four nonfracture NCOs and three early fracture NCOs (before substantial biologic effects of treatment would be expected) were assessed over 1-year and 3-month follow-up periods, respectively. According to comparability decision rules established a priori, patients initiating denosumab were comparable to those initiating zoledronic acid or alendronate, irrespective of prior osteoporosis treatment experience. Among new users, new switchers, and in the historical fracture subgroup, no meaningful differences were observed in the cumulative incidence of the seven NCOs comparing denosumab to zoledronic acid. This empirical examination can assist in the selection of appropriate comparator groups for future comparability research using real-world data. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

27. Supplementing Teachers' and Researchers' Use of Concrete Manipulatives in the Classroom with the Use of Digital Manipulatives.

Author

Kelly, Anthony E. and O'Kelly, James B.

Abstract

Describes the design of a computer-based problem-solving tool for teaching abstraction and classification to elementary school students. The task involves reasoning with attribute blocks. The software keeps a detailed trace of the student's actions, allowing teachers to provide intelligent feedback to the student. Results of a pilot study of the software involving five children are also reported. (MDM)

Published
1994

28. Extending a Tradition: Teacher Designed Computer-Based Games.

Author

Kelly, Anthony E. and O'Kelly, James B.

Abstract

Notes that the emergence of powerful microcomputers, along with accessible authoring systems, allow teachers the opportunity to extend their classroom game design efforts into digital media. Argues that these efforts, for effective and efficient design, should be informed by guidance from literature on instructional game design, educational computing, and computer game design. (HTH)

Published
1994

32. Global epidemiology of hip fractures: a study protocol using a common analytical platform among multiple countries

Author

Sing, Chor-Wing, primary, Lin, Tzu-Chieh, additional, Bartholomew, Sharon, additional, Bell, J Simon, additional, Bennett, Corina, additional, Beyene, Kebede, additional, Bosco‐Lévy, Pauline, additional, Chan, Amy Hai Yan, additional, Chandran, Manju, additional, Cheung, Ching-Lung, additional, Doyon, Caroline Y, additional, Droz-Perroteau, Cécile, additional, Ganesan, Ganga, additional, Hartikainen, Sirpa, additional, Ilomaki, Jenni, additional, Jeong, Han Eol, additional, Kiel, Douglas P, additional, Kubota, Kiyoshi, additional, Lai, Edward Chia-Cheng, additional, Lange, Jeff, additional, Lewiecki, E Michael, additional, Liu, Jiannong, additional, Man, Kenneth K C, additional, Mendes de Abreu, Mirhelen, additional, Moore, Nicolas, additional, O’Kelly, James, additional, Ooba, Nobuhiro, additional, Pedersen, Alma B, additional, Prieto-Alhambra, Daniel, additional, Shin, Ju-Young, additional, Sørensen, Henrik T, additional, Tan, Kelvin Bryan, additional, Tolppanen, Anna-Maija, additional, Verhamme, Katia M C, additional, Wang, Grace Hsin-Min, additional, Watcharathanakij, Sawaeng, additional, Zhao, Hongxin, additional, and Wong, Ian C K, additional

Published
2021
Full Text
View/download PDF

33. Global epidemiology of hip fractures:A study protocol using a common analytical platform among multiple countries

Author

Sing, Chor Wing, Lin, Tzu Chieh, Bartholomew, Sharon, Bell, J. Simon, Bennett, Corina, Beyene, Kebede, Bosco-Lévy, Pauline, Chan, Amy Hai Yan, Chandran, Manju, Cheung, Ching Lung, Doyon, Caroline Y., Droz-Perroteau, Cécile, Ganesan, Ganga, Hartikainen, Sirpa, Ilomaki, Jenni, Jeong, Han Eol, Kiel, Douglas P., Kubota, Kiyoshi, Lai, Edward Chia Cheng, Lange, Jeff, Lewiecki, E. Michael, Liu, Jiannong, Man, Kenneth K.C., Mendes De Abreu, Mirhelen, Moore, Nicolas, O'Kelly, James, Ooba, Nobuhiro, Pedersen, Alma B., Prieto-Alhambra, Daniel, Shin, Ju Young, Sørensen, Henrik T., Tan, Kelvin Bryan, Tolppanen, Anna Maija, Verhamme, Katia M.C., Wang, Grace Hsin Min, Watcharathanakij, Sawaeng, Zhao, Hongxin, Wong, Ian C.K., Sing, Chor Wing, Lin, Tzu Chieh, Bartholomew, Sharon, Bell, J. Simon, Bennett, Corina, Beyene, Kebede, Bosco-Lévy, Pauline, Chan, Amy Hai Yan, Chandran, Manju, Cheung, Ching Lung, Doyon, Caroline Y., Droz-Perroteau, Cécile, Ganesan, Ganga, Hartikainen, Sirpa, Ilomaki, Jenni, Jeong, Han Eol, Kiel, Douglas P., Kubota, Kiyoshi, Lai, Edward Chia Cheng, Lange, Jeff, Lewiecki, E. Michael, Liu, Jiannong, Man, Kenneth K.C., Mendes De Abreu, Mirhelen, Moore, Nicolas, O'Kelly, James, Ooba, Nobuhiro, Pedersen, Alma B., Prieto-Alhambra, Daniel, Shin, Ju Young, Sørensen, Henrik T., Tan, Kelvin Bryan, Tolppanen, Anna Maija, Verhamme, Katia M.C., Wang, Grace Hsin Min, Watcharathanakij, Sawaeng, Zhao, Hongxin, and Wong, Ian C.K.

Abstract

Introduction Hip fractures are associated with a high burden of morbidity and mortality. Globally, there is wide variation in the incidence of hip fracture in people aged 50 years and older. Longitudinal and cross-geographical comparisons of health data can provide insights on aetiology, risk factors, and healthcare practices. However, systematic reviews of studies that use different methods and study periods do not permit direct comparison across geographical regions. Thus, the objective of this study is to investigate global secular trends in hip fracture incidence, mortality and use of postfracture pharmacological treatment across Asia, Oceania, North and South America, and Western and Northern Europe using a unified methodology applied to health records. Methods and analysis This retrospective cohort study will use a common protocol and an analytical common data model approach to examine incidence of hip fracture across population-based databases in different geographical regions and healthcare settings. The study period will be from 2005 to 2018 subject to data availability in study sites. Patients aged 50 years and older and hospitalised due to hip fracture during the study period will be included. The primary outcome will be expressed as the annual incidence of hip fracture. Secondary outcomes will be the pharmacological treatment rate and mortality within 12 months following initial hip fracture by year. For the primary outcome, crude and standardised incidence of hip fracture will be reported. Linear regression will be used to test for time trends in the annual incidence. For secondary outcomes, the crude mortality and standardised mortality incidence will be reported. Ethics and dissemination Each participating site will follow the relevant local ethics and regulatory frameworks for study approval. The results of the study will be submitted for peer-reviewed scientific publications and presented at scientific conferences.

Published
2021

39. List of Contributors

Author

Abrams, Steven A., primary, Adams, John S., additional, Adams, Judith E., additional, Adorini, Luciano, additional, Anderson, Paul H., additional, Atkins, Gerald J., additional, Aubin, Jane E., additional, Bailleul-Forestier, Isabelle, additional, Barsony, Julia, additional, Barthel, Thomas K., additional, Bell, Norman H., additional, Berdal, Ariane, additional, Bergh, Joel J., additional, Berry, Jacqueline L., additional, Bikle, Daniel D., additional, Bilezikian, John P., additional, Binderup, Ernst, additional, Binderup, Lise, additional, Bishop, Nicholas J., additional, Bogaerts, Ilse, additional, Boland, Ricardo L., additional, Boskey, Adele L., additional, Bouillon, Roger, additional, Boyan, Barbara D., additional, Brachet, Philippe, additional, Brown, Alex J., additional, Brown, Edward M., additional, Carlberg, Carsten, additional, Carmeliet, Geert, additional, Carpenter, Thomas O., additional, Chapuy, Marie-Claire, additional, Chan, Fredriech K.W., additional, Chen, Tai C., additional, Christakos, Sylvia, additional, Clagett-Dame, Margaret, additional, Clemens, Thomas L., additional, Choi, Je-Yong, additional, Coe, Fredric L., additional, Colston, Kay, additional, Compston, Juliet E., additional, Cooke, Nancy E., additional, Crescioli, Clara, additional, Cross, Heide S., additional, Danilenko, Michael, additional, Davideau, Jean-Luc, additional, Davies, Michael, additional, DeLuca, Hector F., additional, Demay, Marie B., additional, Dhawan, Puneet, additional, Dominguez, Carlos Encinas, additional, Dowd, Diane R., additional, Drezner, Marc K., additional, Dunlop, Thomas W., additional, Dusso, Adriana S., additional, Eastell, Richard, additional, Econs, Michael J., additional, Eisman, John, additional, Epstein, Sol, additional, Eriksen, Erik Fink, additional, Esteban, Luis M., additional, Faibish, Dan, additional, Fang, Yue, additional, Farach-Carson, Mary C., additional, Favus, Murray J., additional, Feldman, David, additional, Findlay, David, additional, Frank, Christian, additional, Freedman, Leonard P., additional, Fujiki, Ryuji, additional, Fukagawa, Masafumi, additional, Gagel, Robert F., additional, Garcion, Emmanuel, additional, Gardiner, Edith M., additional, Gascon-Barré, Marielle, additional, Giovannucci, Edward, additional, Glerup, Henning, additional, Glorieux, Francis H., additional, Godtfredsen, Wagn O., additional, Goltzman, David, additional, Gutierrez, Soraya, additional, Gysemans, Conny, additional, Halloran, Bernard P., additional, Haussler, Carol A., additional, Haussler, Mark R., additional, Heaney, Robert P., additional, Heersche, Johan, additional, Henry, Helen L., additional, Hershberger, Pamela A., additional, Hewison, Martin, additional, Heyman, Richard A., additional, Higashio, Kanji, additional, Holick, Michael F., additional, Hollis, Bruce W., additional, Horst, Ronald L., additional, Hsieh, Jui-Cheng, additional, Insogna, Karl L., additional, Jacobs, Elizabeth T., additional, Javed, Amjad, additional, Jones, Glenville, additional, Johnson, Candace S., additional, Jurutka, Peter W., additional, Kahraman, Mehmet, additional, Zaidi, S. Kaleem, additional, Kalkwarf, Heidi J., additional, Kato, Shigeaki, additional, Kissmeyer, Anne-Marie, additional, Kitagawa, Hirochika, additional, Koberle, Lilia M.C., additional, Koeffler, H. Phillip, additional, Koren, Ruth, additional, Kream, Barbara E., additional, Kremer, Richard, additional, Krishnan, Aruna V., additional, Kubodera, Noboru, additional, Kumar, Rajiv, additional, Kurokawa, Kiyoshi, additional, Laing, Christopher J., additional, Lemire, Jacques, additional, Lézot, Frédéric, additional, Li, Yan Chun, additional, Lian, Jane B., additional, Lichtler, Alexander C., additional, Lips, Paul, additional, Liu, Yan, additional, MacDonald, Paul, additional, Maehr, Hubert, additional, Maggi, Mario, additional, Malloy, Peter J., additional, Mangelsdorf, David J., additional, Mathieu, Chantal, additional, May, Brian, additional, Mee, Andrew P., additional, Meunier, Pierre J., additional, Michigami, Toshimi, additional, Montecino, Martin, additional, Moras, Dino, additional, Morosetti, Roberta, additional, Morris, Howard A., additional, Motola, Daniel L., additional, Muindi, Josephia, additional, Nakajima, Shigeo, additional, Naveh-Many, Tally, additional, Naveilhan, Philippe, additional, Neveu, Isabelle, additional, Norman, Anthony W., additional, Nykjaer, Anders, additional, O'Kelly, James, additional, Omdahl, John L., additional, Ordentlich, Peter, additional, Ozono, Keiichi, additional, Parfitt, A. Michael, additional, Peehl, Donna M., additional, Peleg, Sara, additional, Peng, Xiaorong, additional, Pettifor, John M., additional, Pike, J. Wesley, additional, Platz, Elizabeth A., additional, Plum, Lori A., additional, Pockwinse, Shirwin, additional, Pols, Huibert A.P., additional, Portale, Anthony A., additional, Posner, Gary H., additional, Rahmaniyan, Mehrdad, additional, Ravid, Amiram, additional, Reddy, G. Satyanarayana, additional, Reichrath, Jörg, additional, Reinhardt, Timothy A., additional, Reszka, Alfred A., additional, Riggs, B. Lawrence, additional, Rochel, Natacha, additional, Rubin, Mishaela R., additional, Russo, Andrew F., additional, Sambrook, Philip, additional, Schneider, Adina E., additional, Schwartz, Gary G., additional, Schwartz, Zvi, additional, Shen, Jiali, additional, Shevde, Nirupama K., additional, Sicinski, Rafal R., additional, Silver, Justin, additional, Slatopolsky, Eduardo A., additional, Specker, Bonny L., additional, St-Arnaud, René, additional, Stein, Gary S., additional, Stein, Janet L., additional, Stern, Paula H., additional, Studzinski, George P., additional, Suda, Tatsuo, additional, Sutton, Amelia L.M., additional, Tebben, Peter, additional, Tenenhouse, Harriet S., additional, Thatcher, Michelle L., additional, Thys-Jacobs, Susan, additional, Towler, Dwight A., additional, Trump, Donald L., additional, Uitterlinden, André G., additional, Uskoković, Milan R., additional, Väisänen, Sami, additional, Van Baelen, Hugo, additional, Van Cromphaut, Sophie, additional, van Leeuwen, Johannes P.T.M., additional, van Meurs, Joyce B.J., additional, van Wijnen, Andre J., additional, Verboven, Christel, additional, Vieth, Reinhold, additional, Wasserman, Robert H., additional, Welsh, JoEllen, additional, Whitfield, G. Kerr, additional, Whyte, Michael P., additional, Willnow, Thomas, additional, Wion, Didier, additional, Yasuda, Hisataka, additional, Young, Daniel, additional, and Zhang, Chi, additional

Published
2005
Full Text
View/download PDF

47. Association between preadmission frailty and care level at discharge in older adults undergoing emergency laparotomy

Author

Carter, B, primary, Law, J, additional, Hewitt, J, additional, Parmar, K L, additional, Boyle, J M, additional, Casey, P, additional, Maitra, I, additional, Pearce, L, additional, Moug, S J, additional, Ross, Bryony, additional, Oleksiewicz, Julia, additional, Fearnhead, Nicola, additional, Jump, Christopher, additional, Boyle, Jemma, additional, Shaw, Alex, additional, Barker, Jonathan, additional, Hughes, Jane, additional, Randall, Jonathan, additional, Tonga, Isileli, additional, Kynaston, James, additional, Boal, Matthew, additional, Eardley, Nicola, additional, Kane, Elizabeth, additional, Reader, Harriet, additional, Mahapatra, Sunanda Roy, additional, Garner-Jones, Michael, additional, Tan, Jessica Juliana, additional, Mohamed, Said, additional, George, Rina, additional, Whiteman, Ed, additional, Malik, Kamran, additional, Smart, Christopher J, additional, Bogdan, Monica, additional, Chaudhury, Madhu Parna, additional, Sharma, Videha, additional, Subar, Daren, additional, Patel, Panna, additional, Chok, Sok-Moi, additional, Lim, Evelyn, additional, Adhiyaman, Vedamurthy, additional, Davies, Glesni, additional, Ross, Ellen, additional, Maitra, Rudra, additional, Steele, Colin W, additional, Roxburgh, Campbell, additional, Griffiths, Shelly, additional, Blencowe, Natalie S, additional, Kirkham, Emily N, additional, Abraham, John S, additional, Griffiths, Kirsty, additional, Abdulaal, Yasser, additional, Iqbal, Muhammad Rafaih, additional, Tarazi, Munir, additional, Hill, James, additional, Khan, Azam, additional, Farrell, Ian, additional, Conn, Gemma, additional, Patel, Jugal, additional, Reddy, Hyder, additional, Sarveswaran, Janahan, additional, Arunachalam, Lakshmanan, additional, Malik, Afaq, additional, Ponchietti, Luca, additional, Pawelec, Krystian, additional, Goh, Yan Mei, additional, Vitish-Sharma, Parveen, additional, Saad, Ahmed, additional, Smyth, Edward, additional, Crees, Amy, additional, Merker, Louise, additional, Bashir, Nahida, additional, Williams, Gethin, additional, Hayes, Jennifer, additional, Walters, Kelly, additional, Harries, Rhiannon, additional, Singh, Rahulpreet, additional, Henderson, Nikola A, additional, Polignano, Francesco M, additional, Knight, Ben, additional, Alder, Louise, additional, Kenchington, Alexandra, additional, Goh, Yan Li, additional, Dicurzio, Ilaria, additional, Griffiths, Ewen, additional, Alani, Ahmed, additional, Knight, Katrina, additional, MacGoey, Patrick, additional, Ng, Guat Shi, additional, Mackenzie, Naomi, additional, Maitra, Ishaan, additional, Moug, Susan, additional, Ong, Kelly, additional, McGrath, Daniel, additional, Gammeri, Emanuele, additional, Lafaurie, Guillame, additional, Faulkner, Gemma, additional, Di Benedetto, Gabriele, additional, McGovern, Julia, additional, Subramanian, Bharathi, additional, Narang, Sunil Kumar, additional, Nowers, Jennifer, additional, Smart, Neil J, additional, Daniels, Ian R, additional, Varcada, Massimo, additional, Gala, Tanzeela, additional, Cornish, Julie, additional, Barber, Zoe, additional, O'Neill, Stephen, additional, McGregor, Richard, additional, Robertson, Andrew G, additional, Paterson-Brown, Simon, additional, Raymond, Thomas, additional, Thaha, Mohamed A, additional, English, William J, additional, Forde, Cillian T, additional, Paine, Heidi, additional, Morawala, Alpa, additional, Date, Ravindra, additional, Casey, Patrick, additional, Bolton, Thomas, additional, Gleaves, Xuan, additional, Fasuyi, Joshua, additional, Durakovic, Sanja, additional, Dunstan, Matt, additional, Allen, Sophie, additional, Riga, Angela, additional, Epstein, Jonathan, additional, Pearce, Lyndsay, additional, Gaines, Emily, additional, Howe, Anthony, additional, Choonara, Halima, additional, Dewi, Ffion, additional, Bennett, Joanne, additional, King, Emile, additional, McCarthy, Kathryn, additional, Taylor, Greg, additional, Harris, Dean, additional, Nageswaran, Hari, additional, Stimpson, Amy, additional, Siddiqui, Kamran, additional, Lim, Lay In, additional, Ray, Christopher, additional, Smith, Laura, additional, McColl, Gillian, additional, Rahman, Mohammed, additional, Kler, Aaron, additional, Sharma, Abhi, additional, Parmar, Kat, additional, Patel, Neil, additional, Crofts, Perry, additional, Baldari, Claudio, additional, Thomas, Rhys, additional, Stechman, Michael, additional, Aldridge, Roland, additional, O'Kelly, James, additional, Wilson, Graeme, additional, Gallegos, Nicholas, additional, Kalaiselvan, Ramya, additional, Rajaganeshan, Rajasundaram, additional, Mackenzie, Aliya, additional, Naik, Prashant, additional, Singh, Kaushiki, additional, Gandraspulli, Harinath, additional, Wilson, Jeremy, additional, Hancorn, Kate, additional, Khawaja, Amir, additional, Nicholas, Felix, additional, Marks, Thomas, additional, Abbott, Cameron, additional, and Chandler, Susan, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results